AstraZeneca’s Kevin Horgan Joins Seres as Chief Medical Officer

Kevin Horgan has been appointed executive vice president and chief medical officer of Seres Therapeutics (NASDAQ: [[ticker:MCRB]]). Horgan succeeds Michele Trucksis, who will continue to consult for the Cambridge, MA, microbiome drugs developer. Seres gave no reason for Tucksis’s departure. In a securities filing, the company said that she gave notice of her resignation on Oct. 17 and will remain employed at Seres through Nov. 16.

Horgan was most recently vice president of clinical development at AstraZeneca (NYSE: [[ticker:AZN]]). His experience also includes co-founding microbiome diagnostics company Tucana Health. Seres’s lead drug candidate, an experimental treatment for Clostridium difficile infection, is in late-stage clinical testing.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times. View all posts by Frank Vinluan